Get started
Author

Taizo Uchimoto

Observed names: T. Uchimoto, T., Uchimoto, TAIZO UCHIMOTO, Taizo Uchimoto*, Uchimoto, Taizo, 内本, 泰三
ORCID: 0000-0002-5200-9053
Observed ORCID: 0000-0002-5200-9053
OpenAlex ID: A5111276394
microRNA-145 Mediates the Inhibitory Effect of Adipose Tissue-Derived Stromal Cells on Prostate Cancer
2016 · Kiyoshi Takahara, Masaaki Ii, et al. · Stem Cells and Development · 129
Incidence of urethral stricture after bipolar transurethral resection of the prostate using TUR is: results from a randomised trial
2014 · Kazumasa Komura, Teruo Inamoto, et al. · British Journal of Urology · 70
A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder
2018 · Teruo Inamoto, Hirofumi Uehara, et al. · Disease Markers · 47
PDF
Increased BUB1B/BUBR1 expression contributes to aberrant DNA repair activity leading to resistance to DNA-damaging agents
2021 · Kazumasa Komura, Teruo Inamoto, et al. · Oncogene · 38
PDF
Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study
2023 · Wataru Fukuokaya, Yuhei Koike, et al. · International Journal of Urology · 32
Preoperative Measurement of the Modified Glasgow Prognostic Score Predicts Patient Survival in Non-Metastatic Renal Cell Carcinoma Prior to Nephrectomy
2017 · Takuya Tsujino, Kazumasa Komura, et al. · Annals of Surgical Oncology · 30
Intravesical administration of exogenous microRNA-145 as a therapy for mouse orthotopic human bladder cancer xenograft
2015 · Teruo Inamoto, Kohei Taniguchi, et al. · Oncotarget · 30
PDF
Prognostic impact of C-reactive protein-albumin ratio for the lethality in castration-resistant prostate cancer
2019 · Taizo Uchimoto, Kazumasa Komura, et al. · Medical Oncology · 26
Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan
2024 · Yosuke Hirasawa, Takahiro Adachi, et al. · Journal of Cancer Research and Clinical Oncology · 24
PDF
Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors
2022 · Wataru Fukuokaya, Takahiro Kimura, et al. · Urologic Oncology Seminars and Original Investigations · 24
Comparison of Radiographic Progression-Free Survival and PSA Response on Sequential Treatment Using Abiraterone and Enzalutamide for Newly Diagnosed Castration-Resistant Prostate Cancer: A Propensity Score Matched Analysis from Multicenter Cohort
2019 · Kazumasa Komura, Yuya Fujiwara, et al. · Journal of Clinical Medicine · 22
PDF
Serum C-reactive Protein Level Predicts Overall Survival for Clear Cell and Non-Clear Cell Renal Cell Carcinoma Treated with Ipilimumab plus Nivolumab
2022 · Yusuke Yano, Takaya Ohno, et al. · Cancers · 21
PDF
Risk Classification for Overall Survival by the Neutrophil–Lymphocyte Ratio and the Number of Metastatic Sites in Patients Treated with Pembrolizumab—A Multicenter Collaborative Study in Japan
2021 · Taizo Uchimoto, Kazumasa Komura, et al. · Cancers · 17
PDF
Could Transurethral Resection of the Prostate Using the TURis System Take Over Conventional Monopolar Transurethral Resection of the Prostate? A Randomized Controlled Trial and Midterm Results
2014 · Kazumasa Komura, Teruo Inamoto, et al. · Urology · 17
Predicting time to castration resistance with androgen-receptor signaling inhibitors in hormone-sensitive prostate cancer: data from ULTRA-Japan Consortium
2024 · Taizo Uchimoto, Kengo Iwatsuki, et al. · International Journal of Clinical Oncology · 16
Dual Gas Treatment With Hydrogen and Carbon Monoxide Attenuates Oxidative Stress and Protects From Renal Ischemia-Reperfusion Injury
2018 · T. Nishida, T. Hayashi, et al. · Transplantation Proceedings · 16
Novel Bladder Preservation Therapy with Osaka Medical College Regimen
2014 · Haruhito Azuma, Teruo Inamoto, et al. · The Journal of Urology · 16
Single session of high-intensity focused ultrasound for localized prostate cancer: treatment outcomes and potential effect as a primary therapy
2013 · Kazumasa Komura, Teruo Inamoto, et al. · World Journal of Urology · 16
PDF
The novel bladder preservation therapy BOAI-CDDP-radiation (OMC-regimen): A new treatment option for invasive bladder cancer patients with lymph node metastasis
2014 · HARUHITO AZUMA, TERUO INAMOTO, et al. · International Journal of Oncology · 15
PDF
Efficacy of pembrolizumab and comprehensive CD274/PD-L1 profiles in patients previously treated with chemoradiation therapy as radical treatment in bladder cancer
2022 · Kazuki Nishimura, Kyosuke Nishio, et al. · Journal for ImmunoTherapy of Cancer · 14
PDF
245 MicroRNA-145 mediates the inhibitory effect of adipose-derived stem cells on androgen-independent prostate cancer
2016 · K. Takahara, T. Inamoto, et al. · European Urology Supplements · 14
Nephron-sparing ureteroscopic surgery vs. radical nephroureterectomy: comparable survival-outcomes in upper tract urothelial carcinoma
2023 · Takuya Tsujino, Kazumasa Komura, et al. · World Journal of Urology · 13
Prognostic value of the fluctuation in the neutrophil–lymphocyte ratio at 6 weeks of pembrolizumab treatment is specific to the clinical response in metastatic urothelial carcinoma
2022 · Taizo Uchimoto, Ko Nakamura, et al. · Urologic Oncology Seminars and Original Investigations · 13
C-Reactive Protein-Albumin Ratio Predicts Objective Response to Enfortumab Vedotin in Metastatic Urothelial Carcinoma
2024 · Taizo Uchimoto, Takuya Matsuda, et al. · Targeted Oncology · 12
Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors
2024 · Taizo Uchimoto, Shuya Tsuchida, et al. · Targeted Oncology · 10
Works count: 74
Citation count: 783
H-index: 16
I10-index: 26
Year
Topic
Type